Related Experiment Videos
Standard versus high-dose therapy in 10+ breast cancer
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Early-Life Air Pollution Exposure Is Associated with the Infant Gut Microbiome and Fecal Metabolome in the First Two Years of Life.
Research report (Health Effects Institute)·2026
PRISM-Seq: An Ultra-sensitive Sequencing Approach For Mapping Lentiviral Integration Sites.
bioRxiv : the preprint server for biology·2026
HIV-1 Integration Site Determines the Transcriptional Fate and Persistence of Integrated Proviruses.
bioRxiv : the preprint server for biology·2026
Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA.
Journal of virus eradication·2023
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026